Toho : Notice Regarding Approval of Partial Amendments to Dosage and Administration of Famciclovir Tablets 250mg “KYOSOMIRAI” and Famciclovir Tablets 250mg “KMP” for KYOSOMIRAI PHARMA(104 KB)
November 31, 2023 at 10:07 pm EDT
Share
November 1, 2023
To whom it may concern:
Company Name
TOHO HOLDINGS CO., LTD.
Corporate
Atsushi Udoh, Representative
Representative
Director, CEO
(Prime Market of Tokyo Stock
Exchange Securities Code: 8129)
Contact:
Makoto Kawamura, Corporate
Officer and General Manager,
Corporate Communications and
Investor Relations Division
(TEL: 81-3-6838-2803)
Notice Regarding Approval of Partial Amendments to Dosage and Administration of
Famciclovir Tablets 250mg "KYOSOMIRAI" and
Famciclovir Tablets 250mg "KMP" for KYOSOMIRAI PHARMA
TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters:Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, received an approval of partial amendments to dosage and administration of Famciclovir Tablets 250mg "KYOSOMIRAI" and Famciclovir Tablets 250mg "KMP" on November 1, 2023 as below.
Outline of Famciclovir Tablets 250mg "KYOSOMIRAI" and Famciclovir Tablets 250mg "KMP"
Class
Product Name
Original Brand Name
Anti-herpesvirus agents
Famciclovir Tablets 250mg "KYOSOMIRAI"
Famvir ®Tablets 250mg
Famciclovir Tablets 250mg " KMP"
Outline of Amendments to Dosage and Administration of Famciclovir Tablets 250mg "KYOSOMIRAI" and Famciclovir Tablets 250mg "KMP"
Indications and
Dosage and Administration
Usage
The usual adult dosage is 250 mg of famciclovir administered orally three times daily.
Herpes simplex In addition, in the case of recurrent herpes simplex, famciclovir 1000 mg orally two
times can usually be given to adults.
Herpes zoster
The usual adult dosage is 500 mg of famciclovir administered orally three times daily.
(Underlined parts are revised parts.)
Attachments
Original Link
Original Document
Permalink
Disclaimer
Toho Holdings Co. Ltd. published this content on 01 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2023 02:06:05 UTC.
Toho Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical wholesale business. The Company operates through five business segments. The Pharmaceutical Wholesale segment purchases pharmaceuticals and medical-related products from pharmaceutical manufacturers and sells them to hospitals, clinics and dispensing pharmacies. It is also engaged in the provision of data processing system and rental of real estate. The Dispensing Pharmacy segment is engaged in the management of insurance dispensing pharmacies and dispensing pharmacies. The Pharmaceutical Manufacture and Sale segment is engaged in the manufacture and sale of generic drugs and contract manufacturing of injectable drugs. The Clinical Trial Facility Support segment is engaged in the provision of support for clinical trial facilities. The Information Equipment Sales segment is engaged in the planning and sale of information processing equipment.
Toho : Notice Regarding Approval of Partial Amendments to Dosage and Administration of Famciclovir Tablets 250mg “KYOSOMIRAI” and Famciclovir Tablets 250mg “KMP” for KYOSOMIRAI PHARMA(104 KB)
TOHO HOLDINGS CO., LTD. 
